Status:
WITHDRAWN
Interferon Alpha-2b (Intron A) for Metastatic or Unresectable Clear Cell Renal Carcinoma
Lead Sponsor:
Ohio State University Comprehensive Cancer Center
Conditions:
Renal Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This study will determine the response rate of daily low dose interferon-alpha-2b in patients with metastatic or unresectable clear cell renal cell carcinoma.
Detailed Description
Rationale: Interferon has long been used as a therapy for renal cell carcinoma. However, optimal dosing schedules have not been identified and patients have been relegated to receiving the highest pos...
Eligibility Criteria
Inclusion
- Metastatic or unresectable clear cell renal cell carcinoma
- Measurable disease
Exclusion
- Prior interferon therapy
- More than 3 prior therapy regimens
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2006
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00293527
End Date
November 1 2006
Last Update
May 23 2013
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.